In vitro readthrough of termination codons by gentamycin in the Stüve-Wiedemann Syndrome

22Citations
Citations of this article
34Readers
Mendeley users who have this article in their library.
Get full text

Abstract

The Stüve-Wiedemann Syndrome (SWS) is a frequently lethal chondrodysplasia caused by null mutations in the leukemia inhibitory factor receptor gene (LIFR) responsible for an impaired activation of the JAK-STAT pathway after LIF stimulation. Most LIFR mutations are nonsense mutations, thus prompting us to investigate the impact of aminoglycosides on the readthrough of premature termination codons (PTCs). Culturing skin fibroblasts from three SWS patients and controls for 48 h in the presence of gentamycin (200-500 g/ml) partially restored the JAK-STAT3 pathway when stimulated by LIF. Consistently, quantitative RT-PCR analysis showed that gentamycin stabilized LIFR mRNAs carrying UGA premature termination codons. We conclude that high gentamycin concentrations can partially restore functional LIFR protein synthesis in vitro, prompting us to investigate PTC readthrough using less toxic and more efficient drugs in this presently untreatable lethal condition. © 2010 Macmillan Publishers Limited All rights reserved.

Cite

CITATION STYLE

APA

Bellais, S., Le Goff, C., Dagoneau, N., Munnich, A., & Cormier-Daire, V. (2010). In vitro readthrough of termination codons by gentamycin in the Stüve-Wiedemann Syndrome. European Journal of Human Genetics, 18(1), 130–132. https://doi.org/10.1038/ejhg.2009.122

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free